Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

Dexamethasone (or just “dex”) is a synthetic ... The route of administration (oral versus IV) should be dictated by the patient condition, as the time of onset is similar [4].

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...

After hours: January 31 at 6:03:38 PM EST Loading Chart for HROW ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Do not use a numbing agent without first speaking with a healthcare provider. And while your skin may benefit from being chilled, you should warm the drug you use to room temperature before ...